Novo Nordisk, Eli Lilly slide after Trump comments on weight loss drug pricing
Investing.com - Apogee (NASDAQ: APOG) reported second quarter EPS of $0.98, $0.14 better than the analyst estimate of $0.84. Revenue for the quarter came in at $358.19M versus the consensus estimate of $351.7M.
Guidance
Apogee sees FY 2026 EPS of $3.60-$3.90 versus the analyst consensus of $3.96.
Apogee sees FY 2026 revenue of $1.39B-$1.42B versus the analyst consensus of $1.42B.
Apogee’s stock price closed at $41.44. It is down -5.69% in the last 3 months and down -47.02% in the last 12 months.
Apogee saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Apogee’s stock price’s past reactions to earnings here.
According to InvestingPro, Apogee’s Financial Health score is "fair performance".
Check out Apogee’s recent earnings performance, and Apogee’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar